In vivo T-cell depletion and pharmacokinetic-based busulfan conditioning regimen improve the outcomes in acute myeloid leukemia (AML) in complete remission undergoing to allogeneic stem cell transplantation.
Where this comes from
- Record sourced from PubMed, PMID 42603134.
- Also identified by DOI 10.1002/cncr.70545 and PMC identifier 13476953.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pharmacokinetic‐based busulfan administration improves the therapeutic window and in vivo T‐cell depletion with antilymphocyte globulins reduces graft‐versus‐host disease incidence. In this study, both were used, showing an improvement of clinical outcomes in patients with acute myeloid leukemia.